CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.
P S
PS
Linsley
J
J
Ledbetter
R
R
Peach
J
J
Bajorath
D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000943:Antigens, Differentiation / Q000378:metabolism*; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen; D001665:Binding Sites; D018106:CD28 Antigens / Q000378:metabolism*; D060908:CTLA-4 Antigen; D006801:Humans; D018796:Immunoconjugates; D008213:Lymphocyte Activation; D008562:Membrane Glycoproteins / Q000378:metabolism; D008954:Models, Biological; D008958:Models, Molecular; D015394:Molecular Structure; D011971:Receptors, Immunologic / Q000737:chemistry* / Q000378:metabolism*; D015398:Signal Transduction; D013601:T-Lymphocytes / Q000276:immunology*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; C497964:CD86 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D008562:Membrane Glycoproteins; D011971:Receptors, Immunologic; D000069594:Abatacept